Kezia Alberto, MD
Nephrology · Florham Park, NJNPI 1073721809
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 433 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 433 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Vifor Pharma, Inc.$1K
- GSK$622
- OPKO Pharmaceuticals, LLC$465
- Bayer$445
- Otsuka America Pharmaceutical, Inc.$432
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$2003%
- Food & beverage$6,86795%
- Education$1292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 85 | $1,459 |
| Vifor Pharma, Inc. | 69 | $1,250 |
| GSK | 36 | $622 |
| OPKO Pharmaceuticals, LLC | 36 | $465 |
| Bayer | 28 | $445 |
| Otsuka America Pharmaceutical, Inc. | 32 | $432 |
| Travere Therapeutics, Inc. | 21 | $391 |
| Novartis | 19 | $325 |
| Amgen(2 entities) | 17 | $261 |
| Ardelyx, Inc. | 14 | $221 |
| Aurinia Pharma U.S., Inc. | 12 | $175 |
| Calliditas Therapeutics US Inc. | 10 | $162 |
| Azurity Pharmaceuticals, Inc. | 7 | $114 |
| Pharmacosmos Therapeutics Inc. | 1 | $109 |
| La Jolla Pharmaceutical Company | 1 | $97 |
| Akebia Therapeutics Inc | 5 | $84 |
| Arbor Pharmaceuticals, Inc. | 6 | $83 |
| Fresenius USA Marketing, Inc. | 3 | $50 |
| Lilly USA, LLC | 3 | $49 |
| ANI Pharmaceuticals, Inc. | 3 | $46 |
| Ultragenyx Pharmaceutical Inc. | 3 | $42 |
| Apellis Pharmaceuticals, Inc. | 2 | $33 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Novo Nordisk | 2 | $29 |
| Mallinckrodt Hospital Products Inc. | 2 | $29 |
| Sanofi | 2 | $29 |
| Mallinckrodt Enterprises LLC | 2 | $26 |
| Shire North American Group Inc | 2 | $25 |
| Invivyd Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Strongbridge US Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
- FARXIGA$125
- BENLYSTA$122
- Monoferric$109
How this compares
$7,196 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 66 | $47,234 |
| VeltassaPatiromer Calcium Sorbitex | 30 | $35,288 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $28,824 |
| EdarbiAzilsartan Medoxomil | 41 | $20,121 |
| KerendiaFinerenone | 16 | $15,599 |
| JardianceEmpagliflozin | 13 | $7,808 |
| Nebivolol Hcl | 90 | $7,277 |
| Febuxostat | 26 | $4,666 |
| SpsSodium Polystyrene Sulfon/Sorb | 20 | $3,932 |
| Eplerenone | 29 | $3,371 |
| Potassium Chloride | 27 | $3,086 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 75 | $2,944 |
| Amlodipine Besylate | 339 | $2,724 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 46 | $2,337 |
| Torsemide | 110 | $2,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,459 | $76,059101 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $83 | $20,12141 claims |
| BayerKerendia | $445 | $15,59916 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $46 | $1,52623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Florham Park
- Jeffrey GoodmanFlorham Park$70K
- Robert ZenenbergFlorham Park$13K
- Seema KaranjgaokarFlorham Park$6K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.